$1.35
1.49%
Downside
Day's Volatility :4.51%
Upside
3.07%
60.37%
Downside
52 Weeks Volatility :84.29%
Upside
60.35%
Period | Allakos Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 92.91% | -0.1% | 0.0% |
6 Months | 7.14% | 4.9% | 0.0% |
1 Year | -28.19% | 16.3% | 0.0% |
3 Years | -98.56% | 11.6% | -27.6% |
Market Capitalization | 125.3M |
Book Value | $0.95 |
Earnings Per Share (EPS) | -2.35 |
Wall Street Target Price | 2.77 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -49.29% |
Return On Equity TTM | -121.54% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -182.5M |
Diluted Eps TTM | -2.35 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.54 |
EPS Estimate Next Year | -0.66 |
EPS Estimate Current Quarter | -0.33 |
EPS Estimate Next Quarter | -0.25 |
What analysts predicted
Upside of 105.19%
Sell
Neutral
Buy
Allakos Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Allakos Inc | 107.66% | 7.14% | -28.19% | -98.56% | -98.19% |
Regeneron Pharmaceuticals, Inc. | -17.98% | -13.74% | 0.21% | 32.39% | 141.22% |
Biontech Se | -10.32% | 19.69% | 8.29% | -55.53% | 471.7% |
Alnylam Pharmaceuticals, Inc. | 0.38% | 78.75% | 60.7% | 44.82% | 192.62% |
Vertex Pharmaceuticals Incorporated | 9.48% | 19.97% | 33.29% | 161.38% | 149.59% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Allakos Inc | NA | NA | NA | -1.54 | -1.22 | -0.49 | NA | 0.95 |
Regeneron Pharmaceuticals, Inc. | 20.53 | 20.53 | 1.2 | 44.89 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.11 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -1.87 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.27 | 0.19 | -0.03 | 0.13 | NA | 60.66 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Allakos Inc | Buy | $125.3M | -98.19% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $91.1B | 141.22% | 20.53 | 33.61% |
Biontech Se | Buy | $25.6B | 471.7% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $35.2B | 192.62% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $128.9B | 149.59% | 32.84 | -4.51% |
Insights on Allakos Inc
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.7% return, outperforming this stock by 88.9%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 143.4%
Bvf Inc
NEA Management Company, LLC
Logos Global Management LP
Deep Track Capital, LP
FMR Inc
Morgan Stanley - Brokerage Accounts
allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.
Organization | Allakos Inc |
Employees | 131 |
CEO | Dr. Robert Alexander Ph.D. |
Industry | Health Technology |
Cactus Acquisition Corp 1 Ltd
$1.35
+0.0%
Rigel Resource Acquisition Corp
$1.35
+0.0%
Bj's Restaurants
$1.35
+0.0%
Blackrock Muniyield Qual Ii
$1.35
+0.0%
John Hancock Income Securities Closed Fund
$1.35
+0.0%
United Homes Group Inc
$1.35
+0.0%
Quantum Fintech Acquisition Corp
$1.35
+0.0%
Invesco Wilderhill Clean Energy Etf
$1.35
+0.0%
Harte Hanks Inc
$1.35
+0.0%